Kala-azar comes to New York

Archives of Internal Medicine

Volumn 157, Issue 8, 1997, Pages 921-923

  Parkas, Valerie ^a   Godwin, Janice ^b   Murray, Henry W ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMASTIGOTE; ARTICLE; CASE REPORT; ENDEMIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROTOZOAL INFECTION; TRAVEL; VISCERAL LEISHMANIASIS;

EID: 0031403352     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.8.921     Document Type: Article

References (20)

1. Montalban C, Calleja JL, Erice A, et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus. J Infect. 1990;21:261-270.
2. Medrano FJ, Hernandez-Quero J, Jimenez E, et al. Visceral leishmaniasis in HIV-1 infected individuals: a common opportunistic infection in Spain. AIDS. 1992;6:1499-1503.
3. Montalban C, Martinez-Fernandez R, Calleja J, et al. Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain. Rev Infect Dis. 1989;11:655-660.
4. Altes J, Salas A, Melchor R, et al. Visceral leishmaniasis: another HIV-associated opportunistic infection? report of eight cases and review of the literature. AIDS. 1991;5:201-207.
5. Rosenthal E, Marty P, Poizot-Martin I, et al. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg. 1995;89:159-162.
6. Chenoweth CE, Singal S, Pearson RD, Betts RF, Markowitz DM. Acquired immunodeficiency syndrome-related visceral leishmaniasis presenting in a pleural effusion. Chest. 1993;103:648-649.
7. Laguna F, Garcia-Samaniego J, Soriano V, et al. Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: report of five cases and review. Clin Infect Dis. 1994;19:48-53.
8. Fillola G, Corberand JX, Laharrague PF, Levenes H, Massip P, Recco P. Peripheral intramonocytic leishmaniasis in an AIDS patient. J Clin Microbiol. 1992;30:3284-3285.
9. Martinez P, de la Vega E, Laguna F, et al. Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears. AIDS. 1990;7:227-230.
10. Murray HW, Oca MJ, Granger A, Schreiber R. Successful response to chemotherapy in experimental visceral leishmaniasis: requirement for T cells and effect of lymphokines. J Clin Invest. 1989;83:1253-1260.
11. Murray HW, Hariprashad J, Fichtl RE. Treatment of experimental visceral leishmaniasis in the T cell-deficient host: response to amphotericin B and pentamidine. Antimicrob Agents Chemother. 1993;37:1504-1505.
12. Torre-Cisneros J, Villanueva JL, Kindelan JM, Jurado R, Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis. 1993;17:625-627.
13. Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med. 1994;87:75-81.
14. Davidson RN, Russo R. Relapse of visceral leishmaniasis in patients who were co-infected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis. 1994;19:560.
15. Murray HW, Hariprashad, Fichtl RE. Models of relapse of experimental visceral leishmaniasis. J Infect Dis. 1996;173:1041-1043.
16. Murray HW. Interferon-gamma in host antimicrobial defense: current and future clinical applications. Am J Med. 1994;97:459-465.
17. Albrecht H, Sobottka I, Emminger C, et al. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med. 1996;120:189-198.
18. Dellamonica P, Bernard E, Le Fichoux Y, et al. Allopurinol for treatment of visceral leishmaniasis in patients with AIDS. J Infect Dis. 1989; 160:904-905.
19. Ribera E, Ocana I, de Otero J, Cortes E, Gasser I. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med. 1996;100:496-501.
20. Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. Treatment of kala-azar with oral fluconazole. Lancet. 1996;348:614.